Risk Factors Update Summary

• As of June 30, 2024, we had 12.5 million shares outstanding, which could dilute voting power. This change might lead to a decline in stock price.
• The company declared a dividend of one preferred share purchase right for each outstanding share. This "poison pill" may discourage hostile takeovers, impacting control dynamics.
• An inability to motivate independent consultants could harm our business and disrupt operations. This change might result in decreased sales and revenue.
• We may face increased scrutiny from tax authorities, potentially raising our effective tax rate. This could lead to fines and back taxes, adversely affecting our financial condition.
• The departure of key independent consultants could distract our business and disrupt operations. This change might lead to a significant negative impact on revenue.
• We must comply with new FDA regulations for cosmetic products, increasing operational costs. Compliance could significantly impact our business and profitability.
• Ongoing geopolitical matters have contributed to significant economic uncertainty, impacting our business and financial results. A decline in consumer discretionary spending could further harm our sales.
• The dietary supplement market is highly competitive, with many competitors having greater resources. This could materially affect our revenue and market share.